Latest News

Nvidia is guiding for 70% top-line growth in its next fiscal year, but the chipmaker has regularly proven too conservative with its guidance in the past.

The software maker is growing faster than ever, yet its shares sit about where they were a year ago. So is the stock finally reasonably priced?

Aurora Innovation (NASDAQ:AUR) is preparing to expand its autonomous-trucking operations through a second-generation hardware rollout, a planned transition toward a driver-as-a-service model and additional manufacturing relationships, Co-founder and CEO Chris Urmson said at the Morgan Stanley Laguna

The unlocking of SpaceX shares is reshaping the communications sector.

The sale of 5,578 shares appears to be a routine transaction.

Yields are rising, and investors are selling REITs, opening up an opportunity to buy reliable, high-yield dividend stocks for long-term investors.

It's one of four key sector holdings in the company's portfolio.

This expensive quantum computing stock isn't growing as fast as it seems.

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

The index has climbed in 34 of the last 41 fourth quarters. The seven misses are the part worth studying.

Coca-Cola isn't cheap, but it is executing well in a difficult market and has an incredible dividend history.

Investors are growing increasingly concerned about AI-powered threats.

Pfizer's rebound is well underway.

SpaceX stock has rebounded nicely since its prior sell-off, but can the momentum last until its next earnings report?

Meta has fallen behind the other frontier labs recently, but that may have changed with the introduction of the Muse app.

WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden. Speaking at Morgan Stanley’s healthcare conference,

Looking back at how five stocks picked specifically to beat the market over just the next year have now fared 10 years later.

The business multiplied over the decade. The stock's price-to-earnings multiple mostly didn't.

Arista Networks and Vertiv Holdings give investors two long-term ways to play the AI boom beyond the crowded chip trade.

DoorDash and Viking are leaders in delivery and cruises, offering investors growth at a reasonable price.

After decades of spinoffs and separations of various parts, GE Aerospace is now trending toward integration.

A look at what would happen if history repeats itself.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

The Canary Staked TRX ETF could be well timed if the Tron network continues growing.

SK Hynix boasts a 44% net margin and trades at 5.8x forward P/E, while AMD commands a 63x multiple despite stronger growth.